Ashwagandha for Women: Hormonal Balance, Stress and Libido Evidence

Research on ashwagandha for women has expanded significantly in the past decade, moving beyond the general cortisol and stress-reduction evidence to include female-specific outcomes — sexual function, hormonal balance during perimenopause, and libido. The picture that emerges is one of a versatile adaptogen with effects that are particularly relevant to the hormonal challenges women face from their 30s onward. This article examines the clinical evidence specifically for female populations, explains the underlying mechanisms, and identifies who is most likely to benefit.

The Evidence Landscape: What Trials Have Tested in Women

Most of the early ashwagandha RCT data came from predominantly or exclusively male populations — the testosterone and muscle strength trials enrolled men almost exclusively. This changed in the 2010s as researchers began specifically designing trials to test ashwagandha in women. The Chandrasekhar et al. (2012) stress trial enrolled both men and women and found significant reductions in serum cortisol and self-reported stress across the mixed cohort. Langade et al. (2019) similarly enrolled both sexes and found improved sleep quality and reduced anxiety. Choudhary et al. (2017) tested ashwagandha on cognitive outcomes including memory and reaction time in a mixed-sex adult population and found consistent improvements.

The most significant female-specific trial to date was published in 2015 by Dongre et al. in the BioMed Research International journal. This double-blind, randomized, placebo-controlled trial enrolled 50 women aged 21–50 with sexual dysfunction and tested KSM-66 ashwagandha at 300 mg twice daily for 8 weeks. The primary outcome was the Female Sexual Function Index (FSFI), a validated questionnaire measuring six domains: desire, arousal, lubrication, orgasm, satisfaction, and pain. The ashwagandha group showed statistically significant improvements across all six domains compared to placebo. The effect was largest for desire and lubrication. Researchers attributed the improvements to cortisol reduction (which, when elevated, directly suppresses libido and arousal), improved psychological wellbeing, and possible direct effects on reproductive tissue.

A second female-specific trial by Majeed et al. (2020) tested Shoden ashwagandha extract in perimenopausal women for 8 weeks and found significant reductions in menopause symptom scores, including hot flashes, mood disturbance, and sleep problems, alongside reductions in FSH levels (a marker of ovarian reserve decline). This remains a small trial in a specialized population, but it's notable as one of the only randomized tests of ashwagandha specifically in perimenopausal women.

The HPA–HPG Axis: How Cortisol Affects Female Hormones

To understand why ashwagandha benefits women specifically, it helps to understand the relationship between the HPA (hypothalamic-pituitary-adrenal) axis — the stress-response system — and the HPG (hypothalamic-pituitary-gonadal) axis, which governs reproductive hormones.

Clinical data on ashwagandha in women spans several health areas:

Health Benefit	Evidence Level	Key Study / Notes	Typical Dose
Stress & Anxiety Reduction	High	Chandrasekhar 2012; Pratte et al. 2014 — significant cortisol reduction	300–600 mg/day
Sexual Function & Libido	Moderate	Dongre et al. 2015 — FSFI scores improved vs placebo in women	300 mg twice daily, 8 weeks
Thyroid Support (subclinical hypothyroid)	Moderate	Sharma et al. 2018 — improved T3/T4 in subclinical hypothyroid patients	600 mg/day
Perimenopausal Symptoms	Limited-Moderate	Menopause-specific RCT data emerging; reduced hot flash frequency reported	300 mg twice daily
Sleep Quality	Moderate-High	Langade et al. 2019 — PSQI improvement; especially relevant in peri/post-menopause	300 mg twice daily
Endurance & Recovery	Limited	General adaptogen effect; limited women-specific athletic data	500–600 mg/day

Under chronic stress, the HPA axis remains chronically activated, producing sustained cortisol elevation. Cortisol has a direct suppressive effect on the HPG axis at multiple levels. It inhibits GnRH (gonadotropin-releasing hormone) at the hypothalamus, suppresses LH and FSH secretion at the pituitary, and reduces the sensitivity of the ovaries to gonadotropin signals. In practical terms: chronic stress reduces estrogen and progesterone production, disrupts menstrual regularity, suppresses libido, and can contribute to anovulatory cycles. This is the biological reason why high-stress periods — career transitions, relationship stress, caregiving demands — so frequently coincide with menstrual irregularities and reduced sexual desire in women.

Ashwagandha's mechanism of action targets precisely this pathway. Multiple trials, including Chandrasekhar et al. (2012) and Pratte et al. (2014) systematic review data, show that KSM-66 ashwagandha consistently reduces serum cortisol by 14–30% in chronically stressed adults. By reducing the cortisol load on the HPG axis, ashwagandha creates more favorable conditions for normal reproductive hormone production — without directly manipulating estrogen or progesterone levels. This is an important distinction: ashwagandha is not an estrogen or progesterone precursor; it supports reproductive hormone function indirectly by reducing the HPA suppression that disrupts it.

Ashwagandha for Stress and Anxiety in Women

Women are approximately twice as likely as men to be diagnosed with anxiety disorders, and they report higher rates of perceived chronic stress across most demographic surveys. This makes the cortisol-reducing evidence for ashwagandha particularly relevant for female populations. The Chandrasekhar et al. (2012) trial — the most-cited ashwagandha stress trial — used a validated stress assessment scale (PSS) and found a 44% reduction in perceived stress scores and a significant reduction in serum cortisol at week 8 in the ashwagandha group (p<0.001). This was a high-quality double-blind, placebo-controlled trial with 64 participants.

Wankhede et al. (2015) tested ashwagandha in resistance-trained adults and found that women in the study showed improvements in muscle recovery and reduced exercise-induced cortisol comparable to the male participants. This suggests that the physical performance and recovery benefits are not sex-limited, though the female-specific analysis was not the trial's primary focus.

For context on how ashwagandha's stress benefits compare to other options, including magnesium, see our review of Ashwagandha for Anxiety: Full Review of Human Trials.

Ashwagandha During Perimenopause and Menopause

Perimenopause — the transitional phase typically beginning in the mid-40s — involves a progressive decline in ovarian follicular reserve, increasing variability in estrogen levels, rising FSH, and symptoms including hot flashes, night sweats, mood instability, sleep disruption, and cognitive changes. This transition overlaps significantly with the period of maximal NAD+ and DHEA decline, creating a multi-system vulnerability window.

The Majeed et al. (2020) trial enrolled 91 perimenopausal women and tested Shoden ashwagandha extract at 240 mg/day for 8 weeks in a randomized double-blind design. The ashwagandha group showed a 72% reduction in FSH levels compared to 37% in the placebo group — a statistically significant difference suggesting an effect on the hypothalamic-pituitary axis that governs the perimenopausal hormonal shift. Menopause symptom scores (hot flashes, insomnia, depression, anxiety, mood swings, joint pain) were significantly reduced in the ashwagandha group, with most improvements reaching significance by week 4. The trial is small and uses a different extract standardization than KSM-66, but the signal is notable as a proof-of-concept for ashwagandha's utility in perimenopausal symptom management.

The mechanism likely involves ashwagandha's dual action: cortisol reduction (reducing HPA-mediated hypothalamic disruption) and withanolide-mediated neuroprotective effects that may stabilize mood and sleep during the hormonal volatility of perimenopause.

Dosing and Safety Considerations for Women

The effective dose range from female-relevant trials is 240–600 mg/day of standardized KSM-66 or equivalent extract. The Dongre sexual function trial used 300 mg twice daily (600 mg/day total). The Majeed perimenopausal trial used 240 mg/day of a different extract. The general stress and anxiety trials used 300 mg twice daily of KSM-66. A reasonable starting dose is 300 mg/day (single dose with dinner or at bedtime), increasing to 600 mg/day if the lower dose does not produce adequate effect at 4 weeks. Bio:sudo KSM-66 Reishi Restore delivers 600 mg of KSM-66 ashwagandha per serving, matching the dose used in most of the larger trials.

Safety in women requires specific consideration of a few situations. First, ashwagandha is traditionally considered an abortifacient in Ayurvedic medicine and should not be taken during pregnancy. This is not just traditional caution — some animal studies have confirmed uterotonic effects at high doses. Pregnant women should not use ashwagandha. Second, women taking thyroid medication should be aware that ashwagandha has been shown in clinical trials to increase T3 and T4 levels; this could potentially amplify thyroid hormone effects and require dose adjustment of levothyroxine or other thyroid medications. Third, women on hormonal contraceptives or HRT should discuss ashwagandha use with their prescribing physician, as the indirect HPG-axis effects, while generally beneficial, introduce a theoretical variable in hormonally sensitive individuals.

For a full safety review, see our detailed article on Ashwagandha Side Effects: What Clinical Evidence Shows.

Who Benefits Most

Women most likely to experience meaningful benefit from ashwagandha supplementation fall into several categories: those with chronic perceived stress and elevated cortisol that is disrupting sleep, mood, or menstrual regularity; women with low libido or sexual dysfunction that has a stress or hormonal basis (as opposed to a structural or relationship basis); perimenopausal women with early vasomotor symptoms, sleep disruption, or mood instability; and women with stress-driven adrenal-HPA patterns that manifest as fatigue, anxiety, and poor recovery from exercise. Women whose primary concern is physical performance or muscle recovery have supporting evidence from mixed-sex trials, though female-specific evidence is thinner here than for the stress and hormonal domains.

Women who are likely to see less benefit from ashwagandha alone: those with clinically diagnosed anxiety disorders who need pharmacological treatment, those whose menstrual or hormonal issues have structural causes (PCOS, endometriosis, fibroids), and those in postmenopause who may need hormone therapy rather than adaptogenic support for their primary symptoms.

Practical Takeaways

• The Dongre 2015 trial is the most direct evidence for ashwagandha's sexual function benefits in women — significant improvements across all FSFI domains at 600 mg/day KSM-66 over 8 weeks.
• Cortisol reduction is the primary mechanism for hormonal benefit — ashwagandha does not directly manipulate estrogen or progesterone, but reduces HPA suppression of the reproductive axis.
• The perimenopausal trial evidence is preliminary but promising, especially for FSH modulation and symptom reduction in the early transitional phase.
• Starting dose: 300 mg/day KSM-66 standardized extract; increase to 600 mg/day if effect is insufficient after 4 weeks.
• Do not use during pregnancy. Discuss with physician if taking thyroid medication or hormonal contraception.
• Allow 6–8 weeks minimum for full effect assessment — cortisol normalization is a gradual process, and the trials consistently showed benefit appearing and increasing across the full trial period.
• For practical dosing guidance, see our full Ashwagandha Dosage Guide.

Bottom Line

The evidence for ashwagandha in women is strongest for stress and anxiety reduction, well-supported by multiple RCTs across mixed-sex and female populations. The female-specific evidence for sexual function is compelling — one well-designed trial showing significant FSFI improvement across all domains — though replication is needed. Perimenopausal symptom management evidence is preliminary but directionally positive. Safety considerations are manageable: the main absolute contraindication is pregnancy, and thyroid medication users require prescriber coordination. For women with stress-driven hormonal symptoms, ashwagandha's HPA axis mechanism makes it one of the most mechanistically appropriate adaptogens available.

References

1. Chandrasekhar K, et al. "A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults." Indian J Psychol Med. 2012;34(3):255–262. [Source]
2. Langade D, et al. "Efficacy and safety of ashwagandha root extract in insomnia and anxiety." Medicine. 2019;98(37):e17186. [Source]
3. Wankhede S, et al. "Examining the effect of Withania somnifera supplementation on muscle strength and recovery." J Int Soc Sports Nutr. 2015;12:43. [Source]
4. Choudhary D, et al. "Efficacy and safety of ashwagandha root extract in improving memory and cognitive functions." J Dietary Suppl. 2017;14(6):599–612. [Source]
5. Pratte MA, et al. "An alternative treatment for anxiety: a systematic review of human trial results reported for the Ayurvedic herb ashwagandha." J Altern Complement Med. 2014;20(12):901–908. [Source]

---

---